Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Ticker Image

US$0

US$208.5m

-2.0%

46.8%

Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

Ocugen, Inc Overview

Industry: Biotechnology

Sector: Healthcare

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherit Read More

Ocugen, Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Ocugen, Inc

Score

Recent News



Earnings Per Share

Score 3.00/5
Ocugen, Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc
In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

Return on Equity

Score 0.67/5
Ocugen, Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

Net Margin

Score 1.04/5
Ocugen, Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

Share Buyback

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

Leverage

Score 3.35/5
Ocugen, Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc , also exhibit high scores.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Ticker Image

Ocugen, Inc

US$0

US$208.5m

-2.0%

46.8%